
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9365927/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology, 2017, 65, 310-335.	7.3	1,520
2	Baveno VII – Renewing consensus in portal hypertension. Journal of Hepatology, 2022, 76, 959-974.	3.7	890
3	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. Journal of Hepatology, 2021, 75, 659-689.	3.7	676
4	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall in Der Medizin, 2017, 38, e16-e47.	1.5	659
5	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019, 70, 172-193.	3.7	608
6	The clinical use of HVPG measurements in chronic liver disease. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 573-582.	17.8	576
7	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. Gastroenterology, 2013, 144, 102-111.e1.	1.3	437
8	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound in Medicine and Biology, 2018, 44, 2419-2440.	1.5	357
9	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and metaâ€analysis. Hepatology, 2015, 61, 526-536.	7.3	286
10	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. Gastroenterology, 2014, 146, 412-419.e3.	1.3	285
11	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology, 2004, 126, 749-755.	1.3	258
12	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate―study. Hepatology, 2016, 64, 2173-2184.	7.3	251
13	The management of portal hypertension: Rational basis, available treatments and future options. Journal of Hepatology, 2008, 48, S68-S92.	3.7	248
14	Assessing portal hypertension in liver diseases. Expert Review of Gastroenterology and Hepatology, 2013, 7, 141-155.	3.0	241
15	Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology, 2011, 54, 555-561.	7.3	240
16	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	1.3	232
17	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology, 2017, 65, 1293-1305.	7.3	225
18	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology, 2017, 66, 1980-1988.	7.3	223

#	Article	IF	CITATIONS
19	Non-invasive evaluation of portal hypertension using ultrasound elastography. Journal of Hepatology, 2017, 67, 399-411.	3.7	211
20	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver–Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in Medicine and Biology, 2020, 46, 2579-2604.	1.5	210
21	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. Journal of Hepatology, 2015, 62, 1068-1075.	3.7	183
22	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. Seminars in Liver Disease, 2006, 26, 348-362.	3.6	182
23	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	1.3	162
24	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	8.1	149
25	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	3.7	149
26	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. Journal of Hepatology, 2012, 56, 103-108.	3.7	142
27	Physical activity and liver diseases. Hepatology, 2016, 63, 1026-1040.	7.3	142
28	A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. Journal of Hepatology, 2018, 69, 308-317.	3.7	142
29	Idiopathic portal hypertension: Natural history and long-term outcome. Hepatology, 2014, 59, 2276-2285.	7.3	132
30	Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis. American Journal of Gastroenterology, 2008, 103, 1159-1167.	0.4	131
31	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2020 – WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall in Der Medizin, 2020, 41, 562-585.	1.5	130
32	Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterology Report, 2017, 5, 79-89.	1.3	117
33	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. Journal of Hepatology, 2009, 51, 279-287.	3.7	116
34	Portal Hypertension and Gastrointestinal Bleeding. Seminars in Liver Disease, 2008, 28, 003-025.	3.6	114
35	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. Journal of Hepatology, 2010, 52, 846-853.	3.7	114
36	Chronic endurance exercise training prevents agingâ€related cognitive decline in healthy older adults: a randomized controlled trial. International Journal of Geriatric Psychiatry, 2010, 25, 1055-1064.	2.7	113

#	Article	IF	CITATIONS
37	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Digestive and Liver Disease, 2012, 44, 855-860.	0.9	113
38	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. Journal of Hepatology, 2018, 69, 878-885.	3.7	113
39	Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. Journal of Hepatology, 2010, 53, 273-282.	3.7	112
40	Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. PLoS ONE, 2013, 8, e58742.	2.5	110
41	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107
42	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. American Journal of Gastroenterology, 2021, 116, 723-732.	0.4	105
43	Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. The Lancet Gastroenterology and Hepatology, 2018, 3, 708-719.	8.1	100
44	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	3.7	97
45	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall in Der Medizin, 2017, 38, 377-394.	1.5	93
46	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 806-815.e5.	4.4	90
47	Update on ultrasound imaging of liver fibrosis. Journal of Hepatology, 2013, 59, 180-182.	3.7	87
48	Ultraschall bei Pfortaderhochdruck – Teil 2 – und EFSUMB-Empfehlungen zurÂDurchführung und Dokumentation von Ultraschalluntersuchungen bei Pfortaderhochdruck. Ultraschall in Der Medizin, 2012, 33, 8-32.	1.5	84
49	Effect of chronic β-blockade on QT interval in patients with liver cirrhosis. Journal of Hepatology, 2008, 48, 415-421.	3.7	83
50	Doppler Ultrasound Findings in the Hepatic Artery Shortly After Liver Transplantation. American Journal of Roentgenology, 2009, 193, 128-135.	2.2	82
51	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology, 2003, 37, 378-384.	7.3	78
52	Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension. Disease Markers, 2011, 31, 129-138.	1.3	76
53	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. Hepatology, 2010, 51, 2108-2116.	7.3	74
54	Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. Gastroenterology, 2016, 150, 982-997.e30.	1.3	73

#	Article	IF	CITATIONS
55	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. Journal of Hepatology, 2021, 75, 1367-1376.	3.7	73
56	Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. Journal of Hepatology, 2009, 50, 296-305.	3.7	72
57	Review article: impact of exercise on physical frailty in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 988-1000.	3.7	72
58	Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. Journal of Gastroenterology, 2011, 46, 687-695.	5.1	70
59	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver International, 2010, 30, 816-825.	3.9	69
60	Systematic review with metaâ€analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 20-30.	3.7	68
61	Ultraschall bei Pfortaderhochdruck – Teil 1. Ultraschall in Der Medizin, 2011, 32, 548-571.	1.5	66
62	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 446-452.	0.4	65
63	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver International, 2014, 34, 16-25.	3.9	64
64	Imaging in clinical decision-making for portal vein thrombosis. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 308-316.	17.8	64
65	Advances and challenges in cirrhosis and portal hypertension. BMC Medicine, 2017, 15, 200.	5.5	64
66	Portal vein thrombosis: The role of imaging in the clinical setting. Digestive and Liver Disease, 2017, 49, 113-120.	0.9	63
67	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound in Medicine and Biology, 2021, 47, 2803-2820.	1.5	63
68	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. Journal of Hepatology, 2019, 71, 942-950.	3.7	61
69	Spleen Enlargement on Follow-Up Evaluation: A Noninvasive Predictor of Complications of Portal Hypertension in Cirrhosis. Clinical Gastroenterology and Hepatology, 2008, 6, 1129-1134.	4.4	58
70	Prevention and treatment of variceal haemorrhage in 2017. Liver International, 2017, 37, 104-115.	3.9	57
71	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. American Journal of Clinical Nutrition, 2012, 96, 584-590.	4.7	50
72	Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver International, 2005, 25, 331-336.	3.9	49

#	Article	IF	CITATIONS
73	Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction. American Journal of Gastroenterology, 2005, 100, 2696-2701.	0.4	49
74	Novel ultrasound-based methods to assess liver disease: The game has just begun. Digestive and Liver Disease, 2018, 50, 107-112.	0.9	49
75	Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut, 2015, 64, 657-666.	12.1	48
76	Benefits, Open questions and Challenges of the use of Ultrasound inÂthe COVID-19 pandemic era. The views of a panel of worldwide international experts. Ultraschall in Der Medizin, 2020, 41, 228-236.	1.5	46
77	Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology, 2014, 60, 633-647.	7.3	44
78	Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation. Liver Transplantation, 2006, 12, 105-111.	2.4	43
79	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. Journal of Hepatology, 2011, 55, 307-314.	3.7	43
80	Renovascular Impedance Correlates with Portal Pressure in Patients with Liver Cirrhosis. Radiology, 2006, 240, 581-586.	7.3	42
81	Reliability Criteria for Liver Stiffness Measurements with Real-Time 2D Shear Wave Elastography in Different Clinical Scenarios of Chronic Liver Disease. Ultraschall in Der Medizin, 2017, 38, 648-654.	1.5	42
82	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	4.4	42
83	Porto-sinusoidal vascular disorder. Journal of Hepatology, 2022, 77, 1124-1135.	3.7	41
84	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. Digestive and Liver Disease, 2004, 36, 406-411.	0.9	40
85	NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study. American Journal of Gastroenterology, 2010, 105, 1094-1101.	0.4	40
86	Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension. Digestive and Liver Disease, 2015, 47, 411-416.	0.9	40
87	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut, 2022, 71, 402-414.	12.1	39
88	Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. GastroenterologÃa Y HepatologÃa, 2012, 35, 488-495.	0.5	37
89	Pharmacologic Management of Portal Hypertension. Clinics in Liver Disease, 2014, 18, 303-317.	2.1	37
90	Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Disease Markers, 2011, 31, 129-38.	1.3	36

#	Article	IF	CITATIONS
91	Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. Journal of Hepatology, 2014, 60, 910-912.	3.7	35
92	Nuclear deformation mediates liver cell mechanosensing in cirrhosis. JHEP Reports, 2020, 2, 100145.	4.9	35
93	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
94	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. World Journal of Gastroenterology, 2013, 19, 1193.	3.3	34
95	New abdominal collaterals at ultrasound: A clue of progression of portal hypertension. Digestive and Liver Disease, 2008, 40, 62-67.	0.9	33
96	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology, 2020, 72, 1353-1365.	7.3	32
97	Refractory Acute Variceal Bleeding: What to Do Next?. Clinics in Liver Disease, 2010, 14, 297-305.	2.1	30
98	Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. American Journal of Gastroenterology, 2013, 108, 926-932.	0.4	28
99	Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. Hepatology, 2014, 59, 729-731.	7.3	28
100	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. American Journal of Gastroenterology, 2013, 108, 75-82.	0.4	27
101	Muscle psoas indices measured by ultrasound in cirrhosis — Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. Digestive and Liver Disease, 2019, 51, 1502-1507.	0.9	27
102	Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. Journal of Hepatology, 2010, 52, 45-53.	3.7	26
103	Patients Whose First Episode of Bleeding Occurs While Taking a Î ² -Blocker Have High Long-term Risks of Rebleeding and Death. Clinical Gastroenterology and Hepatology, 2012, 10, 670-676.	4.4	26
104	Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. Radiology, 2015, 277, 268-276.	7.3	26
105	Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. Liver International, 2018, 38, 1055-1063.	3.9	26
106	Adipopenia correlates with higher portal pressure in patients with cirrhosis. Liver International, 2019, 39, 1672-1681.	3.9	26
107	Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. Clinics in Liver Disease, 2021, 25, 253-289.	2.1	26
108	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. American Journal of Gastroenterology, 2015, 110, 985-992.	0.4	25

#	Article	IF	CITATIONS
109	Liver MR relaxometry at 3T – segmental normal T1 and T2* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness. Scientific Reports, 2019, 9, 8106.	3.3	25
110	Non-cardiac determinants of NT-proBNP levels in the elderly: Relevance of haematocrit and hepatic steatosis. European Journal of Heart Failure, 2006, 8, 468-476.	7.1	24
111	Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 2101-2109.e1.	4.4	24
112	Insulin resistance in patients with cirrhosis and portal hypertension. American Journal of Physiology - Renal Physiology, 2012, 302, G1458-G1465.	3.4	23
113	Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. GastroenterologÃa Y HepatologÃa, 2013, 36, 527-533.	0.5	23
114	Peliosis hepatis as an early histological finding in idiopathic portal hypertension: A case report. World Journal of Gastroenterology, 2006, 12, 3612.	3.3	23
115	Liver hemangioma and vascular liver diseases in patients with systemic lupus erythematosus. World Journal of Gastroenterology, 2011, 17, 4503.	3.3	23
116	Octreotide in the outpatient therapy of cirrhotic chylous ascites: A case report. Digestive and Liver Disease, 2006, 38, 138-42.	0.9	22
117	Spleen stiffness: Toward a noninvasive portal sphygmomanometer?. Hepatology, 2013, 57, 1278-1280.	7.3	22
118	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. Hepatology Communications, 2018, 2, 933-944.	4.3	21
119	Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 3017-3025.e6.	4.4	21
120	Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs, 2016, 21, 167-181.	2.4	20
121	AISF position paper on liver transplantation and pregnancy. Digestive and Liver Disease, 2016, 48, 860-868.	0.9	20
122	Enfermedades vasculares del hÃgado. GuÃas ClÃnicas de la Sociedad Catalana de DigestologÃa y de la Asociación Española para el Estudio del HÃgado. GastroenterologÃa Y HepatologÃa, 2017, 40, 538-580.	0.5	20
123	Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. Journal of Hepatology, 2006, 44, 310-316.	3.7	19
124	Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scandinavian Journal of Gastroenterology, 2012, 47, 1494-1500.	1.5	19
125	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. Clinical Gastroenterology and Hepatology, 2021, 19, 777-787.e17.	4.4	19
126	Splanchnic haemodynamics in patients with coeliac disease: effects of a gluten-free diet. Digestive and Liver Disease, 2003, 35, 262-268.	0.9	18

#	Article	IF	CITATIONS
127	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. Liver International, 2015, 35, 695-703.	3.9	18
128	Liverâ€related and extrahepatic events in patients with nonâ€alcoholic fatty liver disease: a retrospective competing risks analysis. Alimentary Pharmacology and Therapeutics, 2022, 55, 604-615.	3.7	18
129	Portal hypertension and liver cirrhosis in rats: effect of the β ₃ â€adrenoceptor agonist SR58611A. British Journal of Pharmacology, 2012, 167, 1137-1147.	5.4	17
130	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. Journal of Hepatology, 2013, 59, 717-722.	3.7	17
131	Contrast-enhanced imaging in hepatic epithelioid hemangioendothelioma: retrospective study of 10 patients. Zeitschrift Fur Gastroenterologie, 2019, 57, 753-766.	0.5	17
132	Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver International, 2019, 39, 705-713.	3.9	17
133	Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. Liver International, 2020, 40, 1151-1158.	3.9	17
134	Liver MRI susceptibility-weighted imaging (SWI) compared to T2* mapping in the presence of steatosis and fibrosis. European Journal of Radiology, 2019, 118, 66-74.	2.6	16
135	Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review. Digestive and Liver Disease, 2021, 53, 937-949.	0.9	16
136	Metabolomics as a diagnostic tool for idiopathic non irrhotic portal hypertension. Liver International, 2016, 36, 1051-1058.	3.9	15
137	Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature. Digestive and Liver Disease, 2018, 50, 401-407.	0.9	14
138	A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients. American Journal of Gastroenterology, 2010, 105, 1917-1921.	0.4	13
139	Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. European Journal of Radiology, 2022, 147, 110010.	2.6	13
140	Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by twoâ€dimensional shear wave elastography in nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 102-111.	3.9	13
141	Ultrasonography in Liver Vascular Disease. Ultraschall in Der Medizin, 2018, 39, 382-405.	1.5	12
142	CT predicts liver fibrosis: Prospective evaluation of morphology- and attenuation-based quantitative scores in routine portal venous abdominal scans. PLoS ONE, 2018, 13, e0199611.	2.5	12
143	Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. Reviews on Recent Clinical Trials, 2015, 9, 170-177.	0.8	12
144	Current treatment options of refractory ascites in liver cirrhosis – A systematic review and meta-analysis. Digestive and Liver Disease, 2022, 54, 1007-1014.	0.9	12

#	Article	IF	CITATIONS
145	Prognosis of acute variceal bleeding: Is being on betaâ€blockers an aggravating factor? A shortâ€term survival analysis. Hepatology, 2015, 62, 1840-1846.	7.3	11
146	Imaging and minimally invasive endovascular therapy in the management of portal vein thrombosis. Abdominal Radiology, 2018, 43, 1931-1946.	2.1	11
147	Hepatic sinusoidal hemophagocytosis with and without hemophagocytic lymphohistiocytosis. PLoS ONE, 2019, 14, e0226899.	2.5	11
148	Management of Lifestyle Factors in Individuals with Cirrhosis: A Pragmatic Review. Seminars in Liver Disease, 2020, 40, 020-028.	3.6	11
149	Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. Digestive and Liver Disease, 2020, 52, 958-965.	0.9	11
150	Which preoperative assessment modalities best identify patients who are suitable for enhanced recovery after liver transplantation? A systematic review of the literature and expert panel recommendations. Clinical Transplantation, 2022, 36, e14644.	1.6	11
151	Prevention of recurrent variceal bleeding. Digestive and Liver Disease, 2008, 40, 337-342.	0.9	10
152	"Torsade de pointes―during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. Digestive and Liver Disease, 2009, 41, 535-538.	0.9	10
153	Clinical Evaluation and Prognosis. Digestive Diseases, 2015, 33, 515-523.	1.9	10
154	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. GastroenterologÃa Y HepatologAa (English Edition), 2017, 40, 538-580.	0.1	10
155	Diagnostic hepatic haemodynamic techniques: safety and radiation exposure. Liver International, 2017, 37, 148-154.	3.9	10
156	Physical Activity in Liver Transplantation: A Patient's and Physicians' Experience. Advances in Therapy, 2018, 35, 1729-1734.	2.9	10
157	T1 mapping of the liver and the spleen in patients with liver fibrosis—does normalization to the blood pool increase the predictive value?. European Radiology, 2021, 31, 4308-4318.	4.5	10
158	Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases. Seminars in Liver Disease, 2021, 41, 448-460.	3.6	9
159	Transient elastography and prognosis of cirrhosis. Hepatology, 2012, 55, 1629-1631.	7.3	8
160	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. Liver Transplantation, 2013, 19, 450-456.	2.4	8
161	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2015, 261, e105.	4.2	8
162	Cuantificación de la fibrosis hepática mediante biomarcadores de imagen. Radiologia, 2018, 60, 74-84.	0.5	8

#	Article	IF	CITATIONS
163	LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension. Journal of Hepatology, 2019, 70, e127.	3.7	8
164	Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. United European Gastroenterology Journal, 2020, 8, 961-969.	3.8	8
165	Malnutrition and Alcohol in Patients Presenting with Severe Complications of Cirrhosis After Laparoscopic Bariatric Surgery. Obesity Surgery, 2021, 31, 2817-2822.	2.1	8
166	Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. Obesity Surgery, 2021, 31, 702-711.	2.1	7
167	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). Canadian Liver Journal, 2022, 5, 61-90.	0.9	7
168	Postprandial splanchnic haemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein. European Journal of Gastroenterology and Hepatology, 2004, 16, 1339-1345.	1.6	6
169	Isolated hepatic tuberculoma after orthotopic liver transplantation: a case report. Internal and Emergency Medicine, 2006, 1, 314-316.	2.0	6
170	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. Liver International, 2013, 33, 1454-1456.	3.9	5
171	Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus― Journal of Hepatology, 2015, 63, 1049-1050.	3.7	5
172	Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound: the CLEVER study. Journal of Hepatology, 2018, 68, S76-S77.	3.7	5
173	T1 reduction rate with Gd-EOB-DTPA determines liver function on both 1.5ÂT and 3ÂT MRI. Scientific Reports, 2022, 12, 4716.	3.3	5
174	Age Dependency of Regional Impedance Indices Regardless of Clinical Stage in Patients with Cirrhosis of the Liver. Ultraschall in Der Medizin, 2009, 30, 277-285.	1.5	4
175	Regarding "liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution― Hepatology, 2014, 59, 350-351.	7.3	4
176	Non-invasive Measurement of Portal Pressure. Current Hepatology Reports, 2019, 18, 20-27.	0.9	4
177	Letter: nonselective betaâ€blockers, endoscopic therapy and portal vein thrombosis in cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1370-1371.	3.7	4
178	Liver segmental volume and attenuation ratio (LSVAR) on portal venous CT scans improves the detection of clinically significant liver fibrosis compared to liver segmental volume ratio (LSVR). Abdominal Radiology, 2021, 46, 1912-1921.	2.1	4
179	Noninvasive assessment of clinically significant portal hypertension using ΔT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI. European Journal of Radiology, 2021, 144, 109958.	2.6	4
180	Noninvasive Assessment of <i>Schistosoma</i> â€Related Periportal Fibrosis. Journal of Ultrasound in Medicine, 2021, 40, 2273-2287.	1.7	4

#	Article	IF	CITATIONS
181	Screening for hepatocellular carcinoma among adults with HIV/HBV co-infection in Zambia: a pilot study. International Journal of Infectious Diseases, 2022, 116, 391-396.	3.3	4
182	A cholestatic pattern predicts major liverâ€related outcomes in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 1037-1048.	3.9	4
183	Simvastatin ammeliorates the increased hepatic vascular tone in patients with cirrhosis. Journal of Hepatology, 2003, 38, 12.	3.7	3
184	O017A : Non-invasive tools and risk of varices and clinically significant portal hypertension in compensated cirrhosis: the "anticipate―study. Journal of Hepatology, 2015, 62, S198-S199.	3.7	3
185	Editorial: increased cardiac output in cirrhosis – nonâ€invasive assessment of regional blood flow by magnetic resonance angiography. Alimentary Pharmacology and Therapeutics, 2016, 43, 1340-1342.	3.7	3
186	FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2396-2398.e3.	4.4	3
187	Session 3: Prevention of the Formation of Varices (Pre-Primary Prophylaxis). , 0, , 103-151.		3
188	Resolution of Precapillary Pulmonary Hypertension After Liver Transplantation for Hereditary Hemorrhagic Telangiectasia: Systematic Review and Case Report. Transplantation Proceedings, 2022, 54, 135-143.	0.6	3
189	422 IDIOPATHIC PORTAL HYPERTENSION: IMPACT OF HEPATIC VEIN CATHETERIZATION AND TRANSIENT ELASTOGRAPHY ON ITS DIAGNOSIS. Journal of Hepatology, 2010, 52, S172.	3.7	2
190	New Tools for the Noninvasive Assessment of Cirrhosis. Current Hepatology Reports, 0, , .	0.9	2
191	Portal Vein Thrombosis in Patients with Cirrhosis. Incidence and Factors Associated with Its Development. Journal of Hepatology, 2016, 64, S260.	3.7	2
192	Reply:. Hepatology, 2017, 66, 302-303.	7.3	2
193	A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond. Journal of Hepatology, 2018, 68, S75-S76.	3.7	2
194	A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis. Journal of Hepatology, 2020, 73, S711-S712.	3.7	2
195	Royal Free Hospitalâ€estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. Liver International, 2021, 41, 819-827.	3.9	2
196	Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis. Current Hepatology Reports, 2021, 20, 61-76.	0.9	2
197	Resistance to thrombomodulin correlates with liver stiffness in chronic liver disease a prospective single-center cohort study. Thrombosis Research, 2021, 207, 40-49.	1.7	2
198	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101925.	1.5	2

#	Article	IF	CITATIONS
199	Factors predicting mortality after TIPS for refractory ascites: A single center experience. Digestive and Liver Disease, 2009, 41, A42.	0.9	1
200	739 CIRCULATING AND HEPATIC ENDOCANNABINOIDS AND ENDOCANNABINOID-RELATED MOLECULES IN PATIENTS WITH LIVER CIRRHOSIS. Journal of Hepatology, 2009, 50, S271-S272.	3.7	1
201	621 IMPROVING RISK PREDICTION IN ACUTE VARICEAL BLEEDING WITH OBJECTIVE VARIABLES: THE ROLE OF MELD. Journal of Hepatology, 2013, 58, S254.	3.7	1
202	P518 HEPATIC VENOUS PRESSURE GRADIENT, ASA CLASS AND TYPE OF SURGERY ARE PROGNOSTIC FACTORS OF EXTRA-HEPATIC SURGERY IN PATIENTS WITH CIRRHOSIS: A MULTI-CENTER PROSPECTIVE OBSERVATIONAL STUDY. Journal of Hepatology, 2014, 60, S242.	3.7	1
203	O074 : A metabolomic study of serum from patients with cirrhosis identifies 2 metabolites that accurately predict the acute HVPG response to β-blocker therapy. Journal of Hepatology, 2015, 62, S227-S228.	3.7	1
204	Controlled attenuation parameter as an additional tool for the non-invasive prediction of first clinical decompensation in compensated advanced chronic liver disease. Journal of Hepatology, 2017, 66, S91-S92.	3.7	1
205	Editorial: use of betaâ€blockers and of band ligation in preventing first and recurrent variceal bleeding—"real life―vs evidenceâ€based decisions. Alimentary Pharmacology and Therapeutics, 2018, 47, 1222-1223.	3.7	1
206	Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study. Digestive and Liver Disease, 2018, 50, 33.	0.9	1
207	Controlled attenuation parameter reflects intrahepatic fat content in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2018, 68, S638.	3.7	1
208	13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH. Journal of Hepatology, 2018, 68, S115.	3.7	1
209	SAT-104-Factors associated with renal replacement therapy and mortality following first episode of acute kidney injury in inpatients with cirrhosis. Journal of Hepatology, 2019, 70, e674-e675.	3.7	1
210	FRI-113-Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins. Journal of Hepatology, 2019, 70, e437.	3.7	1
211	SAT-083-Simple non-invasive surrogates of portal hypertension predict clinical decompensation in overweight/obses patientes with cACLD. Journal of Hepatology, 2019, 70, e664-e665.	3.7	1
212	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. Journal of Hepatology, 2020, 73, S751-S752.	3.7	1
213	Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis. Journal of Hepatology, 2020, 73, S696.	3.7	1
214	Sarcopenia correlates with mortality in cirrhotic patients who undergo transjugular intrahepatic portosystemic shunt creation for refractory ascites. Digestive and Liver Disease, 2020, 52, e62.	0.9	1
215	Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. , 2020, , 115-139.		1
216	Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update― Journal of Hepatology, 2022, 76, 251-252.	3.7	1

ANNALISA BERZIGOTTI

#	Article	IF	CITATIONS
217	Development of and Gathering Validity Evidence for a Theoretical Test in Contrast-Enhanced Ultrasound. Ultrasound in Medicine and Biology, 2022, 48, 248-256.	1.5	1
218	205 Age-related changes of splanchnic hemodynamics in patients with liver cirrhosis. Journal of Hepatology, 2004, 40, 66.	3.7	0
219	237 Long-term beta-blockade shortens QT interval prolongation in patients with liver cirrhosis. Journal of Hepatology, 2006, 44, S95.	3.7	0
220	673 Prevalence and factors associated with fatty liver in a geriatric population: Results from the pianoro study. Journal of Hepatology, 2006, 44, S248.	3.7	0
221	Sixty years is not an age limit in patients submitted to liver transplantation. Digestive and Liver Disease, 2007, 39, A40.	0.9	0
222	178 COMPARISON OF ULTRASONOGRAPHIC EVALUATION OF LIVER SURFACE AND TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF CIRRHOSIS AND PORTAL HYPERTENSION. Journal of Hepatology, 2009, 50, S74-S75.	3.7	0
223	748 EFFECT OF B3-ADRENOCEPTOR MODULATION ON PORTAL PRESSURE IN RATS WITH COMPENSATED CIRRHOSIS. Journal of Hepatology, 2009, 50, S275.	3.7	0
224	198 RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS FOR THE REDUCTION OF PORTAL PRESSURE: A META-ANALYSIS AND SYSTEMATIC REVIEW. Journal of Hepatology, 2010, 52, S85-S86.	3.7	0
225	508 INSULIN RESISTANCE AND DIABETES DO NOT INFLUENCE HEPATIC AND SYSTEMIC HEMODYNAMICS OR THE HVPG RESPONSE TO PROPRANOLOL IN PATIENTS WITH CIRRHOSIS. Journal of Hepatology, 2010, 52, S205.	3.7	0
226	F-4 Hemodynamic response to beta-blockers for portal hypertension: A single center experience. Digestive and Liver Disease, 2011, 43, S93.	0.9	0
227	590 ASSESSMENT OF SYSTEMIC ENDOTHELIAL FUNCTION IN PATIENTS WITH CIRRHOSIS: COMPARISON BETWEEN PERIPHERAL ARTERIAL TONOMETRY (PAT) AND BRACHIAL ARTERY VASODILATATION BY ULTRASOUND (BAUS). Journal of Hepatology, 2011, 54, S240.	3.7	0
228	Routine blood tests? Helping you live(r) longer!. Lancet, The, 2011, 378, 2048.	13.7	0
229	193 RELIABILITY OF THE ESTIMATION OF HEPATIC BLOOD FLOW (HBF) BY DOPPLER ULTRASOUND IN PATIENTS WITH CIRRHOTIC PORTAL HYPERTENSION: COMPARISON WITH HBF BY INDOCYANINE GREEN. Journal of Hepatology, 2013, 58, S85.	3.7	0
230	Reply. Gastroenterology, 2013, 144, 1153-1154.	1.3	0
231	P460 A METABOLOMIC PROFILE INCLUDING 5 LIPIDIC METABOLITES CORRELATES WITH DIAGNOSIS OF IDIOPATHIC PORTAL HYPERTENSION. Journal of Hepatology, 2014, 60, S222.	3.7	0
232	Reply. Hepatology, 2015, 62, 978-979.	7.3	0
233	Diagnostic accuracy of liver and spleen stiffness measurement for portal hypertension using bidimensional shear weave elastography. Digestive and Liver Disease, 2015, 47, e18.	0.9	0
234	Reply. Hepatology, 2017, 65, 2131-2132.	7.3	0

#	Article	IF	CITATIONS
235	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life. An international cohort study. Digestive and Liver Disease, 2017, 49, e65.	0.9	0
236	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study. Journal of Hepatology, 2017, 66, S386.	3.7	0
237	Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease. Digestive and Liver Disease, 2018, 50, 48.	0.9	0
238	Reply. Hepatology, 2018, 67, 1645-1646.	7.3	0
239	Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study. Digestive and Liver Disease, 2018, 50, 3-4.	0.9	0
240	A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond. Digestive and Liver Disease, 2018, 50, 33-34.	0.9	0
241	Hepatic Venous Pressure Measurement and Other Diagnostic Hepatic Hemodynamic Techniques. , 2018, , 33-48.		0
242	Noninvasvie prediction of oesophageal varics by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study. Journal of Hepatology, 2018, 68, S96-S97.	3.7	0
243	Subcutaneous adipose tissue is a predictor of survival in patients with hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S423.	3.7	0
244	Clinically significant portal hypertension in chronic liver disease: Always cirrhosis?. Journal of Hepatology, 2018, 68, S734.	3.7	0
245	Outcomes of intrahepatic porto-systemic shunt in the treatment of portal vein thrombosis: A systematic review and meta-analysis. Journal of Hepatology, 2018, 68, S734.	3.7	0
246	SAT-133-2D-Shear-Wave elastography predicts survival in advanced chronic liver disease. Journal of Hepatology, 2019, 70, e689.	3.7	0
247	SAT-021-How to use platelets and liver stiffness to rule out esophageal varices needing treatment?. Journal of Hepatology, 2019, 70, e634-e635.	3.7	0
248	SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis. Journal of Hepatology, 2019, 70, e670.	3.7	0
249	Effect of rifaximin or norfloxacin on hepatic venous pressure gradient in patients with cirrhosis: a systematic review and meta-analysis. Journal of Hepatology, 2020, 73, S772-S773.	3.7	0
250	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. Digestive and Liver Disease, 2020, 52, e60.	0.9	0
251	OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2021, 53, S3-S4.	0.9	0

Assessing Disease Severity and Prognosis. , 2021, , 173-190.

#	Article	IF	CITATIONS
253	Pathophysiology of portal hypertension and variceal bleeding. , 2009, , 137-148.		Ο
254	Use of Vasoactive Drugs for Acute Variceal Bleeding. , 2014, , 135-145.		0
255	Results of the Questionnaire. , 2016, , 31-37.		Ο
256	Portal Hypertension and a Stiff Liver. Cureus, 2018, 10, e2768.	0.5	0
257	Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications. , 2020, , 325-359.		Ο
258	Exercise Interventions for Cirrhosis. Current Treatment Options in Gastroenterology, 0, , .	0.8	0